DexCom Price Target Raised by Morgan Stanley to $89.00, Maintains Equal-Weight Rating
PorAinvest
martes, 15 de julio de 2025, 9:09 pm ET1 min de lectura
DXCM--
The update was released on July 15, 2025, and has caught the attention of investors monitoring DexCom within the healthcare sector. The adjustment suggests Morgan Stanley's acknowledgment of improving metrics or growth potential within DexCom's operations, warranting the raised price outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 26 analysts, the average target price for DexCom Inc (DXCM) is $99.82 with a high estimate of $115.00 and a low estimate of $82.00. The average target implies an upside of 16.98% from the current price of $85.33 [1].
Based on the consensus recommendation from 28 brokerage firms, DexCom Inc's (DXCM) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell [1].
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM) in one year is $169.00, suggesting an upside of 98.05% from the current price of $85.33. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance [1].
References
[1] https://www.gurufocus.com/news/2978108/dexcom-dxcm-price-target-raised-by-morgan-stanley-dxcm-stock-news
MS--
Morgan Stanley has raised its price target for DexCom (DXCM) to $89.00, an 8.54% increase from the previous target of $82.00. The analyst maintains an "Equal-Weight" rating for the stock, indicating a neutral stance on its expected performance. The average target price for DXCM is $99.82, with an upside of 16.98% from the current price of $85.33.
Morgan Stanley has updated its price target for DexCom (DXCM), one of the leaders in glucose monitoring technology. The new price target set by analyst Patrick Wood is $89.00, up from the previous target of $82.00. This revision marks an 8.54% increase from the prior target, reflecting a more optimistic view on the future performance of DexCom. Despite the increase in the price target, Morgan Stanley maintains its "Equal-Weight" rating for (DXCM), indicating a neutral stance on the stock's expected performance relative to the broader market [1].The update was released on July 15, 2025, and has caught the attention of investors monitoring DexCom within the healthcare sector. The adjustment suggests Morgan Stanley's acknowledgment of improving metrics or growth potential within DexCom's operations, warranting the raised price outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 26 analysts, the average target price for DexCom Inc (DXCM) is $99.82 with a high estimate of $115.00 and a low estimate of $82.00. The average target implies an upside of 16.98% from the current price of $85.33 [1].
Based on the consensus recommendation from 28 brokerage firms, DexCom Inc's (DXCM) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell [1].
Based on GuruFocus estimates, the estimated GF Value for DexCom Inc (DXCM) in one year is $169.00, suggesting an upside of 98.05% from the current price of $85.33. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance [1].
References
[1] https://www.gurufocus.com/news/2978108/dexcom-dxcm-price-target-raised-by-morgan-stanley-dxcm-stock-news

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios